These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 18925934

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
    J Mol Biol; 2004 Jun 25; 340(1):9-14. PubMed ID: 15184018
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP, Bryson S, Nieva JL, Pai EF.
    J Mol Biol; 2008 Dec 12; 384(2):377-92. PubMed ID: 18824005
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD.
    AIDS Rev; 2003 Dec 12; 5(4):214-21. PubMed ID: 15012000
    [Abstract] [Full Text] [Related]

  • 10. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, Izumi K, Sakagami Y, Oishi S, Ohkubo T, Kobayashi Y, Otaka A, Fujii N, Matsuoka M.
    Int J Biochem Cell Biol; 2009 Apr 12; 41(4):891-9. PubMed ID: 18834950
    [Abstract] [Full Text] [Related]

  • 13. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
    de la Arada I, Julien JP, de la Torre BG, Huarte N, Andreu D, Pai EF, Arrondo JL, Nieva JL.
    J Phys Chem B; 2009 Oct 15; 113(41):13626-37. PubMed ID: 19754136
    [Abstract] [Full Text] [Related]

  • 14. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
    Cai L, Jiang S.
    ChemMedChem; 2010 Nov 08; 5(11):1813-24. PubMed ID: 20845360
    [Abstract] [Full Text] [Related]

  • 15. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.
    Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, Lu M, An Z, Ingallinella P, Finotto M, Mattu M, Finnefrock AC, Bramhill D, Cook J, Eckert DM, Hampton R, Patel M, Jarantow S, Joyce J, Ciliberto G, Cortese R, Lu P, Strohl W, Schleif W, McElhaugh M, Lane S, Lloyd C, Lowe D, Osbourn J, Vaughan T, Emini E, Barbato G, Kim PS, Hazuda DJ, Shiver JW, Pessi A.
    Proc Natl Acad Sci U S A; 2005 Oct 11; 102(41):14759-64. PubMed ID: 16203977
    [Abstract] [Full Text] [Related]

  • 16. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI.
    Chembiochem; 2009 Apr 17; 10(6):1032-44. PubMed ID: 19283693
    [Abstract] [Full Text] [Related]

  • 17. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S, Borrego P, Ding X, Zhu Y, Martins A, Chong H, Taveira N, He Y.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795437
    [Abstract] [Full Text] [Related]

  • 18. Current peptide HIV type-1 fusion inhibitors.
    Pang W, Tam SC, Zheng YT.
    Antivir Chem Chemother; 2009 Sep 25; 20(1):1-18. PubMed ID: 19794228
    [Abstract] [Full Text] [Related]

  • 19. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y.
    FASEB J; 2013 Mar 25; 27(3):1203-13. PubMed ID: 23233535
    [Abstract] [Full Text] [Related]

  • 20. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
    Sánchez-Martín MJ, Urbán P, Pujol M, Haro I, Alsina MA, Busquets MA.
    Chemphyschem; 2011 Oct 24; 12(15):2816-22. PubMed ID: 21905195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.